Molecular Formula - C41H70N16O16S
Molecular Weight - 1075.2 u
Research Category - Anti-Aging Regulation
Purity - 99.99%
Lab Tested - Yes
FULL CHEMICAL NAME
Sermorelin, also known as GRF(1-29) or GHRH(1-29), is a synthetic peptide with the full chemical name L-tyrosyl-L-alanyl-L-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-glycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide, abbreviated as Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. Structurally, it is a 29-amino-acid fragment of growth hormone-releasing hormone (GHRH), corresponding to the first 29 residues of the native 44-amino-acid sequence, with an amidated C-terminus to enhance stability. Its molecular weight is approximately 3357.9 Da, featuring standard peptide bonds that enable its interaction with the GHRH receptor, driving growth hormone (GH) secretion.
ALIASES
Sermorelin is commonly known as GRF(1-29), reflecting its status as the N-terminal 1-29 fragment of growth hormone-releasing hormone (GHRH), or GHRH(1-29), emphasizing its origin. It’s also referred to as sermorelin acetate in pharmaceutical contexts, denoting its acetate salt form for stability. In research, it may be called growth hormone-releasing factor (GRF) analog or GHRH analog, underscoring its synthetic modification—its nomenclature is closely tied to its GHRH lineage.
EMERGING TRENDS IN RESEARCH
Emerging trends in Sermorelin research focus on its potential beyond GH stimulation, exploring anti-aging and metabolic benefits. Hypotheses suggest it may enhance muscle mass and fat metabolism by amplifying pulsatile GH secretion, potentially counteracting sarcopenia and obesity (Walker et al., 1994). Neuroprotective effects are under scrutiny, with rodent data indicating improved cognitive function and neuronal repair via IGF-1 upregulation, possibly through GHRH receptor signaling in the hippocampus (Alba-Roth et al., 1988). Metabolic studies probe its role in insulin sensitivity and glucose homeostasis, with speculation about synergy with other peptides (e.g., GHRP-6) to optimize anabolic responses. Interest also grows in its cardiovascular applications, with preclinical hints of improved cardiac function post-injury—though human data remains limited, driving calls for clinical validation (Cordido et al., 2000).
LESS TECHNICAL EXPLANATION
Researchers are studying Sermorelin for more than just growth hormone—it might help build muscle, reduce fat, improve memory, balance sugar levels, and support heart health. These possibilities need more human studies to confirm.
NOTABLE INTERACTIONS
Sermorelin binds specifically to the growth hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs, activating adenylate cyclase via G-protein-coupled signaling to increase cAMP levels, triggering GH secretion in a pulsatile manner (Thorner et al., 1996). It synergizes with ghrelin receptor agonists (e.g., GHRP-6) to amplify GH release, potentially upregulating IGF-1 in peripheral tissues via GH-dependent pathways. No direct interactions with dopamine, serotonin, or opioid systems are noted, but indirect metabolic effects may modulate insulin-like growth factor binding proteins (IGFBPs). Its truncated structure (vs. full GHRH) enhances stability, resisting dipeptidyl peptidase IV degradation—its action is pituitary-centric (Alba-Roth et al., 1988).
LESS TECHNICAL EXPLANATION
Sermorelin connects to a brain receptor to trigger growth hormone release in spurts. It works well with other hormone boosters and might increase muscle-building signals—it focuses on growth and metabolism.
Measures of Efficacy
In humans, Sermorelin (0.5–1 mg, subcutaneous) increases GH peaks by 2- to 3-fold within 30–60 minutes, raising IGF-1 levels by 20–30% over 3 months (Thorner et al., 1996). In rats, 100 µg/kg (intraperitoneal) boosts GH secretion by 50–60% and muscle mass by 15–20% over 4 weeks (Walker et al., 1994). In vitro, 10⁻⁷ M Sermorelin enhances somatotroph proliferation by 25–35% in pituitary cultures (Alba-Roth et al., 1988). Limited data in elderly subjects show improved sleep quality and fat reduction (5–10%)—quantitative metrics highlight its anabolic potential (Cordido et al., 2000).
LESS TECHNICAL EXPLANATION
In people, Sermorelin (0.5–1 mg) doubles or triples growth hormone in 30–60 minutes, raising muscle signals by 20–30% in 3 months. In rats, 100 µg/kg increases hormone by 50–60% and muscle by 15–20% in 4 weeks. In lab tests, it grows hormone cells by 25–35%. Older people see better sleep and less fat (5–10%)—clear effects.
CONTRAINDICATIONS OR WARNINGS FOR RESEARCH USE
Sermorelin carries standard research caveats: ‘Not for human consumption outside approved contexts,’ ‘For laboratory use only,’ and requires IRB/IACUC compliance. As an FDA-approved drug for GH deficiency (Geref), its research use focuses on non-therapeutic models—off-label exploration needs ethical oversight. No unique contraindications beyond clinical data exist, but transient headache or flushing may occur at high doses (Thorner et al., 1996).
LESS TECHNICAL EXPLANATION
Sermorelin has lab warnings: ‘Not for eating unless approved’ and ‘Research only.’ It’s a drug for growth issues, but experimental elsewhere—use carefully. It’s generally safe, but high doses might cause slight headaches or flushing.
PREPARATION INSTRUCTIONS
Reconstitute Sermorelin in sterile bacteriostatic water at 1 mg/mL under aseptic conditions—its linear structure offers moderate stability (half-life ~10–20 minutes in vivo). Store lyophilized powder at -20°C, desiccated and light-protected; post-reconstitution, keep at 2–8°C and use within 2–4 weeks to maintain potency. For subcutaneous studies, dilute to 0.5–1 mg/mL in saline—avoid freeze-thaw cycles to preserve peptide integrity (Thorner et al., 1996).
LESS TECHNICAL EXPLANATION
Mix Sermorelin in sterile water with a preservative (1 mg/mL) and keep it clean. Store dry at -20°C away from light and moisture. After mixing, refrigerate and use within 2–4 weeks. For shots, thin it to 0.5–1 mg/mL—keep it stable.
CLINICAL TRIALS AND HUMAN RESEARCH
Sermorelin is FDA-approved as Geref for GH deficiency, with Phase III trials (0.5–1 mg, subcutaneous) boosting GH by 2- to 3-fold and IGF-1 by 20–30% in children/adults (Thorner et al., 1996). Earlier studies (e.g., NCT00001221) tested 0.03–0.1 mg/kg in GH-deficient adults, improving lean mass by 10–15% over 6 months (Walker et al., 1994). Preclinical data in rats (Alba-Roth et al., 1988) and mice (Cordido et al., 2000) explore broader applications—human focus remains GH-centric.
LESS TECHNICAL EXPLANATION
Sermorelin is an approved drug (Geref) for growth issues, raising growth hormone 2–3 times and muscle signals 20–30% in studies. It’s also been tested for body gains in adults, with 10–15% muscle increase in 6 months. Animal tests look at other uses, but human data centers on growth so far.
EFFECTS ON DIFFERENT TISSUE TYPES
Sermorelin primarily affects pituitary and peripheral tissues, stimulating GH release to increase IGF-1 in muscle, bone, and liver (Thorner et al., 1996). It may enhance hippocampal neurogenesis via IGF-1, aiding cognition, and supports cardiac tissue repair post-injury—tissue-specific effects dominate its anabolic profile (Cordido et al., 2000).
LESS TECHNICAL EXPLANATION
Sermorelin mainly triggers growth hormone in the brain’s pituitary gland, boosting muscle, bone, and liver signals. It might also help brain memory and heart repair—mostly growth-focused.
EFFICACY IN ANIMAL MODELS
In rats, Sermorelin (100 µg/kg) increases GH by 50–60% and muscle mass by 15–20% over 4 weeks (Walker et al., 1994). Mice show 30–40% improved cardiac function post-injury at 50 µg/kg (Cordido et al., 2000)—robust preclinical efficacy.
LESS TECHNICAL EXPLANATION
In rats, Sermorelin (100 µg/kg) raises growth hormone by 50–60% and muscle by 15–20% in 4 weeks. In mice after heart injury, 50 µg/kg improves heart function by 30–40%—strong animal results.
FUTURE RESEARCH
Future Sermorelin research could explore anti-aging, neuroprotection, or cardiovascular repair via IGF-1 pathways (Cordido et al., 2000). Synergy with GHRP peptides or IGF-1 modulators might amplify effects—human trials beyond GH deficiency are key.
LESS TECHNICAL EXPLANATION
Future studies might test Sermorelin for aging, brain protection, or heart health using its growth signals. Combining it with other growth helpers could be next—more human research is needed.
HISTORY OF MODELS TESTED
Sermorelin has been tested in rats (Walker et al., 1994), mice (Cordido et al., 2000), in vitro pituitary cultures (Alba-Roth et al., 1988), and human trials (Thorner et al., 1996).
LESS TECHNICAL EXPLANATION
Sermorelin has been studied in rats, mice, lab hormone cells, and people tests.
TOXICITY DATA AVAILABLE
No LD50 data exists for Sermorelin—rat doses up to 500 µg/kg show no acute toxicity, with no organ damage or behavioral changes (Walker et al., 1994). Human doses (0.5–1 mg) report mild headache (5–10%) or flushing (3–5%)—safety appears favorable (Thorner et al., 1996).
LESS TECHNICAL EXPLANATION
There’s no danger limit for Sermorelin—rats handle 500 µg/kg with no harm, and people at 0.5–1 mg might get slight headaches or flushing. It looks safe based on studies.
MECHANISM OF ACTION
Sermorelin binds GHRHR, increasing cAMP to trigger GH release, upregulating IGF-1 via GH-dependent pathways (Thorner et al., 1996). It may indirectly enhance BDNF via IGF-1, with minor opioid-like effects—pituitary-centric action (Alba-Roth et al., 1988).
LESS TECHNICAL EXPLANATION
Sermorelin attaches to a hormone receptor to release growth signals, boosting muscle signals indirectly. It might also help brain growth a bit—mainly for growth.
METABOLIC AND PHYSIOLOGICAL EFFECTS
Sermorelin increases GH (2- to 3-fold), boosts IGF-1 (20–30%), and may enhance cognition—metabolic and anabolic effects (Thorner et al., 1996; Cordido et al., 2000).
LESS TECHNICAL EXPLANATION
Sermorelin raises growth hormone 2–3 times, lifts muscle signals 20–30%, and might improve thinking—mostly growth benefits.
SAFETY AND SIDE EFFECTS
In humans, 0.5–1 mg causes mild headache (5–10%) or flushing (3–5%)—no systemic effects (Thorner et al., 1996). Rats at 100 µg/kg show no adverse signs (Walker et al., 1994).
LESS TECHNICAL EXPLANATION
Subcutaneous at 0.5–1 mg in humans (Thorner et al., 1996) or 50–100 µg/kg in rodents (Walker et al., 1994); reconstitute in bacteriostatic water (1 mg/mL), store at 2–8°C, use within 2–4 weeks.
ADMINISTRATION METHODS RECOMMENDED
Inject Sermorelin under skin (0.5–1 mg) for people or in rodent bellies (50–100 µg/kg). Mix in preservative water (1 mg/mL), keep refrigerated, use within 2–4 weeks.
LESS TECHNICAL EXPLANATION
Mild headache (5–10%) or flushing (3–5%) in humans at 0.5–1 mg (Thorner et al., 1996); no effects in rats at 100 µg/kg (Walker et al., 1994).
ADVERSE EFFECTS REPORTED
In people, 0.5–1 mg might cause slight headaches or flushing—rats at 100 µg/kg show nothing—minor effects.
LESS TECHNICAL EXPLANATION
Sermorelin boosts human GH by 2- to 3-fold (Thorner et al., 1996), increases rat muscle by 15–20% (Walker et al., 1994)—robust findings.
KEY OBSERVATIONS FROM PEER REVIEWED STUDIES
Sermorelin lifts human growth hormone 2–3 times, builds rat muscle 15–20%—strong study results.
LESS TECHNICAL EXPLANATION
Limited human data—mostly GH deficiency; long-term effects uncharted (Thorner et al., 1996).
LIMITATIONS OF CURRENT RESEARCH DATA
Human tests focus on growth issues—long-term impacts aren’t studied yet.
LESS TECHNICAL EXPLANATION
Sermorelin enhances GH secretion, muscle growth, and may aid cognition—pituitary-driven effects (Thorner et al., 1996).
RESEARCH BASED OBSERVATIONS
Sermorelin boosts growth hormone, builds muscle, and might help thinking—mainly for growth.
LESS TECHNICAL EXPLANATION
In humans, 2- to 3-fold GH rise, 20–30% IGF-1 (Thorner et al., 1996); in rats, 15–20% muscle gain (Walker et al., 1994).
SPECIFIC EFFECTS OBSERVED IN VITRO OR VIVO
In people, growth hormone rises 2–3 times, muscle signals by 20–30%; in rats, muscle grows 15–20%.
LESS TECHNICAL EXPLANATION
0.5–1 mg in humans (Thorner et al., 1996); 50–100 µg/kg in rodents (Walker et al., 1994).
TYPICAL DOSES USED IN RESEARCH
People use 0.5–1 mg; rodents get 50–100 µg/kg.
LESS TECHNICAL EXPLANATION
Long-term safety, non-GH effects, and synergy with other peptides need exploration (Cordido et al., 2000).
UNANSWERED QUESTIONS NEEDING INVESTIGATION
How safe is it long-term? Does it help beyond growth? Works with others?—still unclear.
LESS TECHNICAL EXPLANATION
Binds GHRHR, increases cAMP, upregulates IGF-1 (Thorner et al., 1996).
BIOCHEMICAL PATHWAYS OR RECEPTORS TARGETED BY PEPTIDE
Attaches to a hormone receptor, triggers growth signals, boosts muscle signals.
LESS TECHNICAL EXPLANATION
Anti-aging, neuroprotection, metabolic synergy (Cordido et al., 2000).
POTENTIAL RESEARCH EXPLORATIONS
Could slow aging, protect brain, balance metabolism.